Bavarian Nordic’s mpox vaccine, Jynneos (MVA-BN), is set to be trialled in pregnant and breastfeeding women and infants. The Phase III trial (PregInPoxVac) will enrol around 350 pregnant women and 250 ...

Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

Is Bavarian Nordic (BVNRY) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Bavarian Nordic is a member of our Medical group ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

The World Health Organization said on Monday, October 14 that it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured, ...

COPENHAGEN, Denmark, October 29, 2024 - Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN ® mpox/smallpox vaccine in children 2 to 11 years of age.